Tissue company looks to cardiovascular repair implant
This article was originally published in Clinica
Executive Summary
US start-up company Reprogenesis has announced plans to begin Phase I trials of a bioactive vascular repair implant within 12 months. The RP-VAD implant combines allogenic endothelial cells with a polymer matrix and is designed to restore the function of endothelial cells lining vessels which have been damaged during surgery or vascular access procedures.